img

Global Virus Like Particles Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Virus Like Particles Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

The global Virus Like Particles market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Virus Like Particles is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
The China market for Virus Like Particles is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
The Europe market for Virus Like Particles is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034..
The global key manufacturers of Virus Like Particles include GlaxoSmithKline, Merck, Novavax, Takeda, Medicago, MedImmune, TechnoVax, Agilvax and Allergy Therapeutics, etc. In 2024, the global top five players hold a share approximately % in sales volume, and in term of revenue of Virus Like Particles, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Virus Like Particles by regions (Countries), company, by type and by type. from 2018 to 2023 and forecast to 2034.
The global Virus Like Particles market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Virus Like Particles market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


GlaxoSmithKline
Merck
Novavax
Takeda
Medicago
MedImmune
TechnoVax
Agilvax
Allergy Therapeutics
Serum Institute of India
GeoVax Labs
Cytos Biotechnology
ANGANY Genetics
CPL Biologicals
Xiamen Innovax Biotech
By Type
Adeno-Associated Virus
HIV
Hepatitis B Virus
Hepatitis C Virus
Others
By Application
Vaccines
Mycoviruses
Virus Research
Therapeutic and Imaging Agents
Others
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Virus Like Particles in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Virus Like Particles manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Virus Like Particles sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Virus Like Particles Definition
1.2 Market by Type
1.2.1 Global Virus Like Particles Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Adeno-Associated Virus
1.2.3 HIV
1.2.4 Hepatitis B Virus
1.2.5 Hepatitis C Virus
1.2.6 Others
1.3 Market Segment by Application
1.3.1 Global Virus Like Particles Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Vaccines
1.3.3 Mycoviruses
1.3.4 Virus Research
1.3.5 Therapeutic and Imaging Agents
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Virus Like Particles Sales
2.1 Global Virus Like Particles Revenue Estimates and Forecasts 2018-2034
2.2 Global Virus Like Particles Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Virus Like Particles Revenue by Region
2.3.1 Global Virus Like Particles Revenue by Region (2018-2023)
2.3.2 Global Virus Like Particles Revenue by Region (2024-2034)
2.4 Global Virus Like Particles Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Virus Like Particles Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Virus Like Particles Sales Quantity by Region
2.6.1 Global Virus Like Particles Sales Quantity by Region (2018-2023)
2.6.2 Global Virus Like Particles Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Virus Like Particles Sales Quantity by Manufacturers
3.1.1 Global Virus Like Particles Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Virus Like Particles Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Virus Like Particles Sales in 2024
3.2 Global Virus Like Particles Revenue by Manufacturers
3.2.1 Global Virus Like Particles Revenue by Manufacturers (2018-2023)
3.2.2 Global Virus Like Particles Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Virus Like Particles Revenue in 2024
3.3 Global Virus Like Particles Sales Price by Manufacturers
3.4 Global Key Players of Virus Like Particles, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Virus Like Particles Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Virus Like Particles, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Virus Like Particles, Product Offered and Application
3.8 Global Key Manufacturers of Virus Like Particles, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Virus Like Particles Sales Quantity by Type
4.1.1 Global Virus Like Particles Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Virus Like Particles Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Virus Like Particles Sales Quantity Market Share by Type (2018-2034)
4.2 Global Virus Like Particles Revenue by Type
4.2.1 Global Virus Like Particles Historical Revenue by Type (2018-2023)
4.2.2 Global Virus Like Particles Forecasted Revenue by Type (2024-2034)
4.2.3 Global Virus Like Particles Revenue Market Share by Type (2018-2034)
4.3 Global Virus Like Particles Price by Type
4.3.1 Global Virus Like Particles Price by Type (2018-2023)
4.3.2 Global Virus Like Particles Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Virus Like Particles Sales Quantity by Application
5.1.1 Global Virus Like Particles Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Virus Like Particles Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Virus Like Particles Sales Quantity Market Share by Application (2018-2034)
5.2 Global Virus Like Particles Revenue by Application
5.2.1 Global Virus Like Particles Historical Revenue by Application (2018-2023)
5.2.2 Global Virus Like Particles Forecasted Revenue by Application (2024-2034)
5.2.3 Global Virus Like Particles Revenue Market Share by Application (2018-2034)
5.3 Global Virus Like Particles Price by Application
5.3.1 Global Virus Like Particles Price by Application (2018-2023)
5.3.2 Global Virus Like Particles Price Forecast by Application (2024-2034)
6 North America
6.1 North America Virus Like Particles Sales by Company
6.1.1 North America Virus Like Particles Revenue by Company (2018-2023)
6.1.2 North America Virus Like Particles Sales Quantity by Company (2018-2023)
6.2 North America Virus Like Particles Market Size by Type
6.2.1 North America Virus Like Particles Sales Quantity by Type (2018-2034)
6.2.2 North America Virus Like Particles Revenue by Type (2018-2034)
6.3 North America Virus Like Particles Market Size by Application
6.3.1 North America Virus Like Particles Sales Quantity by Application (2018-2034)
6.3.2 North America Virus Like Particles Revenue by Application (2018-2034)
6.4 North America Virus Like Particles Market Size by Country
6.4.1 North America Virus Like Particles Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Virus Like Particles Revenue by Country (2018-2034)
6.4.3 North America Virus Like Particles Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Virus Like Particles Sales by Company
7.1.1 Europe Virus Like Particles Sales Quantity by Company (2018-2023)
7.1.2 Europe Virus Like Particles Revenue by Company (2018-2023)
7.2 Europe Virus Like Particles Market Size by Type
7.2.1 Europe Virus Like Particles Sales Quantity by Type (2018-2034)
7.2.2 Europe Virus Like Particles Revenue by Type (2018-2034)
7.3 Europe Virus Like Particles Market Size by Application
7.3.1 Europe Virus Like Particles Sales Quantity by Application (2018-2034)
7.3.2 Europe Virus Like Particles Revenue by Application (2018-2034)
7.4 Europe Virus Like Particles Market Size by Country
7.4.1 Europe Virus Like Particles Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Virus Like Particles Revenue by Country (2018-2034)
7.4.3 Europe Virus Like Particles Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Virus Like Particles Sales by Company
8.1.1 China Virus Like Particles Sales Quantity by Company (2018-2023)
8.1.2 China Virus Like Particles Revenue by Company (2018-2023)
8.2 China Virus Like Particles Market Size by Type
8.2.1 China Virus Like Particles Sales Quantity by Type (2018-2034)
8.2.2 China Virus Like Particles Revenue by Type (2018-2034)
8.3 China Virus Like Particles Market Size by Application
8.3.1 China Virus Like Particles Sales Quantity by Application (2018-2034)
8.3.2 China Virus Like Particles Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Virus Like Particles Sales by Company
9.1.1 APAC Virus Like Particles Sales Quantity by Company (2018-2023)
9.1.2 APAC Virus Like Particles Revenue by Company (2018-2023)
9.2 APAC Virus Like Particles Market Size by Type
9.2.1 APAC Virus Like Particles Sales Quantity by Type (2018-2034)
9.2.2 APAC Virus Like Particles Revenue by Type (2018-2034)
9.3 APAC Virus Like Particles Market Size by Application
9.3.1 APAC Virus Like Particles Sales Quantity by Application (2018-2034)
9.3.2 APAC Virus Like Particles Revenue by Application (2018-2034)
9.4 APAC Virus Like Particles Market Size by Region
9.4.1 APAC Virus Like Particles Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Virus Like Particles Revenue by Region (2018-2034)
9.4.3 APAC Virus Like Particles Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Virus Like Particles Sales by Company
10.1.1 Middle East, Africa and Latin America Virus Like Particles Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Virus Like Particles Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Virus Like Particles Market Size by Type
10.2.1 Middle East, Africa and Latin America Virus Like Particles Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Virus Like Particles Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Virus Like Particles Market Size by Application
10.3.1 Middle East, Africa and Latin America Virus Like Particles Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Virus Like Particles Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Virus Like Particles Market Size by Country
10.4.1 Middle East, Africa and Latin America Virus Like Particles Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Virus Like Particles Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Virus Like Particles Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Information
11.1.2 GlaxoSmithKline Overview
11.1.3 GlaxoSmithKline Virus Like Particles Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 GlaxoSmithKline Virus Like Particles Products and Services
11.1.5 GlaxoSmithKline Virus Like Particles SWOT Analysis
11.1.6 GlaxoSmithKline Recent Developments
11.2 Merck
11.2.1 Merck Company Information
11.2.2 Merck Overview
11.2.3 Merck Virus Like Particles Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Merck Virus Like Particles Products and Services
11.2.5 Merck Virus Like Particles SWOT Analysis
11.2.6 Merck Recent Developments
11.3 Novavax
11.3.1 Novavax Company Information
11.3.2 Novavax Overview
11.3.3 Novavax Virus Like Particles Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Novavax Virus Like Particles Products and Services
11.3.5 Novavax Virus Like Particles SWOT Analysis
11.3.6 Novavax Recent Developments
11.4 Takeda
11.4.1 Takeda Company Information
11.4.2 Takeda Overview
11.4.3 Takeda Virus Like Particles Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 Takeda Virus Like Particles Products and Services
11.4.5 Takeda Virus Like Particles SWOT Analysis
11.4.6 Takeda Recent Developments
11.5 Medicago
11.5.1 Medicago Company Information
11.5.2 Medicago Overview
11.5.3 Medicago Virus Like Particles Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 Medicago Virus Like Particles Products and Services
11.5.5 Medicago Virus Like Particles SWOT Analysis
11.5.6 Medicago Recent Developments
11.6 MedImmune
11.6.1 MedImmune Company Information
11.6.2 MedImmune Overview
11.6.3 MedImmune Virus Like Particles Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 MedImmune Virus Like Particles Products and Services
11.6.5 MedImmune Virus Like Particles SWOT Analysis
11.6.6 MedImmune Recent Developments
11.7 TechnoVax
11.7.1 TechnoVax Company Information
11.7.2 TechnoVax Overview
11.7.3 TechnoVax Virus Like Particles Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 TechnoVax Virus Like Particles Products and Services
11.7.5 TechnoVax Virus Like Particles SWOT Analysis
11.7.6 TechnoVax Recent Developments
11.8 Agilvax
11.8.1 Agilvax Company Information
11.8.2 Agilvax Overview
11.8.3 Agilvax Virus Like Particles Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 Agilvax Virus Like Particles Products and Services
11.8.5 Agilvax Virus Like Particles SWOT Analysis
11.8.6 Agilvax Recent Developments
11.9 Allergy Therapeutics
11.9.1 Allergy Therapeutics Company Information
11.9.2 Allergy Therapeutics Overview
11.9.3 Allergy Therapeutics Virus Like Particles Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.9.4 Allergy Therapeutics Virus Like Particles Products and Services
11.9.5 Allergy Therapeutics Virus Like Particles SWOT Analysis
11.9.6 Allergy Therapeutics Recent Developments
11.10 Serum Institute of India
11.10.1 Serum Institute of India Company Information
11.10.2 Serum Institute of India Overview
11.10.3 Serum Institute of India Virus Like Particles Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.10.4 Serum Institute of India Virus Like Particles Products and Services
11.10.5 Serum Institute of India Virus Like Particles SWOT Analysis
11.10.6 Serum Institute of India Recent Developments
11.11 GeoVax Labs
11.11.1 GeoVax Labs Company Information
11.11.2 GeoVax Labs Overview
11.11.3 GeoVax Labs Virus Like Particles Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.11.4 GeoVax Labs Virus Like Particles Products and Services
11.11.5 GeoVax Labs Recent Developments
11.12 Cytos Biotechnology
11.12.1 Cytos Biotechnology Company Information
11.12.2 Cytos Biotechnology Overview
11.12.3 Cytos Biotechnology Virus Like Particles Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.12.4 Cytos Biotechnology Virus Like Particles Products and Services
11.12.5 Cytos Biotechnology Recent Developments
11.13 ANGANY Genetics
11.13.1 ANGANY Genetics Company Information
11.13.2 ANGANY Genetics Overview
11.13.3 ANGANY Genetics Virus Like Particles Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.13.4 ANGANY Genetics Virus Like Particles Products and Services
11.13.5 ANGANY Genetics Recent Developments
11.14 CPL Biologicals
11.14.1 CPL Biologicals Company Information
11.14.2 CPL Biologicals Overview
11.14.3 CPL Biologicals Virus Like Particles Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.14.4 CPL Biologicals Virus Like Particles Products and Services
11.14.5 CPL Biologicals Recent Developments
11.15 Xiamen Innovax Biotech
11.15.1 Xiamen Innovax Biotech Company Information
11.15.2 Xiamen Innovax Biotech Overview
11.15.3 Xiamen Innovax Biotech Virus Like Particles Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.15.4 Xiamen Innovax Biotech Virus Like Particles Products and Services
11.15.5 Xiamen Innovax Biotech Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Virus Like Particles Value Chain Analysis
12.2 Virus Like Particles Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Virus Like Particles Production Mode & Process
12.4 Virus Like Particles Sales and Marketing
12.4.1 Virus Like Particles Sales Channels
12.4.2 Virus Like Particles Distributors
12.5 Virus Like Particles Customers
13 Market Dynamics
13.1 Virus Like Particles Industry Trends
13.2 Virus Like Particles Market Drivers
13.3 Virus Like Particles Market Challenges
13.4 Virus Like Particles Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Virus Like Particles Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Adeno-Associated Virus
Table 3. Major Manufacturers of HIV
Table 4. Major Manufacturers of Hepatitis B Virus
Table 5. Major Manufacturers of Hepatitis C Virus
Table 6. Major Manufacturers of Others
Table 7. Global Virus Like Particles Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 8. Global Virus Like Particles Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 9. Global Virus Like Particles Revenue by Region (2018-2023) & (US$ Million)
Table 10. Global Virus Like Particles Revenue Market Share by Region (2018-2023)
Table 11. Global Virus Like Particles Revenue by Region (2024-2034) & (US$ Million)
Table 12. Global Virus Like Particles Revenue Market Share by Region (2024-2034)
Table 13. Global Virus Like Particles Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Dose)
Table 14. Global Virus Like Particles Sales by Region (2018-2023) & (K Dose)
Table 15. Global Virus Like Particles Sales Market Share by Region (2018-2023)
Table 16. Global Virus Like Particles Sales by Region (2024-2034) & (K Dose)
Table 17. Global Virus Like Particles Sales Market Share by Region (2024-2034)
Table 18. Global Virus Like Particles Sales Quantity by Manufacturers (2018-2023) & (K Dose)
Table 19. Global Virus Like Particles Sales Quantity Share by Manufacturers (2018-2023)
Table 20. Global Virus Like Particles Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 21. Global Virus Like Particles Revenue Share by Manufacturers (2018-2023)
Table 22. Global Virus Like Particles Price by Manufacturers 2018-2023 (USD/Dose)
Table 23. Global Key Players of Virus Like Particles, Industry Ranking, 2021 VS 2024
Table 24. Global Virus Like Particles Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 25. Global Virus Like Particles by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Virus Like Particles as of 2024)
Table 26. Global Key Manufacturers of Virus Like Particles, Manufacturing Base Distribution and Headquarters
Table 27. Global Key Manufacturers of Virus Like Particles, Product Offered and Application
Table 28. Global Key Manufacturers of Virus Like Particles, Date of Enter into This Industry
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Virus Like Particles Sales Quantity by Type (2018-2023) & (K Dose)
Table 31. Global Virus Like Particles Sales Quantity by Type (2024-2034) & (K Dose)
Table 32. Global Virus Like Particles Sales Quantity Share by Type (2018-2023)
Table 33. Global Virus Like Particles Sales Quantity Share by Type (2024-2034)
Table 34. Global Virus Like Particles Revenue by Type (2018-2023) & (US$ Million)
Table 35. Global Virus Like Particles Revenue by Type (2024-2034) & (US$ Million)
Table 36. Global Virus Like Particles Revenue Share by Type (2018-2023)
Table 37. Global Virus Like Particles Revenue Share by Type (2024-2034)
Table 38. Virus Like Particles Price by Type (2018-2023) & (USD/Dose)
Table 39. Global Virus Like Particles Price Forecast by Type (2024-2034) & (USD/Dose)
Table 40. Global Virus Like Particles Sales Quantity by Application (2018-2023) & (K Dose)
Table 41. Global Virus Like Particles Sales Quantity by Application (2024-2034) & (K Dose)
Table 42. Global Virus Like Particles Sales Quantity Share by Application (2018-2023)
Table 43. Global Virus Like Particles Sales Quantity Share by Application (2024-2034)
Table 44. Global Virus Like Particles Revenue by Application (2018-2023) & (US$ Million)
Table 45. Global Virus Like Particles Revenue by Application (2024-2034) & (US$ Million)
Table 46. Global Virus Like Particles Revenue Share by Application (2018-2023)
Table 47. Global Virus Like Particles Revenue Share by Application (2024-2034)
Table 48. Virus Like Particles Price by Application (2018-2023) & (USD/Dose)
Table 49. Global Virus Like Particles Price Forecast by Application (2024-2034) & (USD/Dose)
Table 50. North America Virus Like Particles Revenue by Company (2018-2023) & (US$ Million)
Table 51. North America Virus Like Particles Sales Quantity by Company (2018-2023) & (K Dose)
Table 52. North America Virus Like Particles Sales Quantity by Type (2018-2023) & (K Dose)
Table 53. North America Virus Like Particles Sales Quantity by Type (2024-2034) & (K Dose)
Table 54. North America Virus Like Particles Revenue by Type (2018-2023) & (US$ Million)
Table 55. North America Virus Like Particles Revenue by Type (2024-2034) & (US$ Million)
Table 56. North America Virus Like Particles Sales Quantity by Application (2018-2023) & (K Dose)
Table 57. North America Virus Like Particles Sales Quantity by Application (2024-2034) & (K Dose)
Table 58. North America Virus Like Particles Revenue by Application (2018-2023) & (US$ Million)
Table 59. North America Virus Like Particles Revenue by Application (2024-2034) & (US$ Million)
Table 60. North America Virus Like Particles Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 61. North America Virus Like Particles Revenue by Country (2018-2023) & (US$ Million)
Table 62. North America Virus Like Particles Revenue by Country (2024-2034) & (US$ Million)
Table 63. North America Virus Like Particles Sales Quantity by Country (2018-2023) & (K Dose)
Table 64. North America Virus Like Particles Sales Quantity by Country (2024-2034) & (K Dose)
Table 65. Europe Virus Like Particles Sales Quantity by Company (2018-2023) & (K Dose)
Table 66. Europe Virus Like Particles Revenue by Company (2018-2023) & (US$ Million)
Table 67. Europe Virus Like Particles Sales Quantity by Type (2018-2023) & (K Dose)
Table 68. Europe Virus Like Particles Sales Quantity by Type (2024-2034) & (K Dose)
Table 69. Europe Virus Like Particles Revenue by Type (2018-2023) & (US$ Million)
Table 70. Europe Virus Like Particles Revenue by Type (2024-2034) & (US$ Million)
Table 71. Europe Virus Like Particles Sales Quantity by Application (2018-2023) & (K Dose)
Table 72. Europe Virus Like Particles Sales Quantity by Application (2024-2034) & (K Dose)
Table 73. Europe Virus Like Particles Revenue by Application (2018-2023) & (US$ Million)
Table 74. Europe Virus Like Particles Revenue by Application (2024-2034) & (US$ Million)
Table 75. Europe Virus Like Particles Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 76. Europe Virus Like Particles Revenue by Country (2018-2023) & (US$ Million)
Table 77. Europe Virus Like Particles Revenue by Country (2024-2034) & (US$ Million)
Table 78. Europe Virus Like Particles Sales Quantity by Country (2018-2023) & (K Dose)
Table 79. Europe Virus Like Particles Sales Quantity by Country (2024-2034) & (K Dose)
Table 80. China Virus Like Particles Sales Quantity by Company (2018-2023) & (K Dose)
Table 81. China Virus Like Particles Revenue by Company (2018-2023) & (US$ Million)
Table 82. China Virus Like Particles Sales Quantity by Type (2018-2023) & (K Dose)
Table 83. China Virus Like Particles Sales Quantity by Type (2024-2034) & (K Dose)
Table 84. China Virus Like Particles Revenue by Type (2018-2023) & (US$ Million)
Table 85. China Virus Like Particles Revenue by Type (2024-2034) & (US$ Million)
Table 86. China Virus Like Particles Sales Quantity by Application (2018-2023) & (K Dose)
Table 87. China Virus Like Particles Sales Quantity by Application (2024-2034) & (K Dose)
Table 88. China Virus Like Particles Revenue by Application (2018-2023) & (US$ Million)
Table 89. China Virus Like Particles Revenue by Application (2024-2034) & (US$ Million)
Table 90. APAC Virus Like Particles Sales Quantity by Company (2018-2023) & (K Dose)
Table 91. APAC Virus Like Particles Revenue by Company (2018-2023) & (US$ Million)
Table 92. APAC Virus Like Particles Sales Quantity by Type (2018-2023) & (K Dose)
Table 93. APAC Virus Like Particles Sales Quantity by Type (2024-2034) & (K Dose)
Table 94. APAC Virus Like Particles Revenue by Type (2018-2023) & (US$ Million)
Table 95. APAC Virus Like Particles Revenue by Type (2024-2034) & (US$ Million)
Table 96. APAC Virus Like Particles Sales Quantity by Application (2018-2023) & (K Dose)
Table 97. APAC Virus Like Particles Sales Quantity by Application (2024-2034) & (K Dose)
Table 98. APAC Virus Like Particles Revenue by Application (2018-2023) & (US$ Million)
Table 99. APAC Virus Like Particles Revenue by Application (2024-2034) & (US$ Million)
Table 100. APAC Virus Like Particles Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 101. APAC Virus Like Particles Revenue by Region (2018-2023) & (US$ Million)
Table 102. APAC Virus Like Particles Revenue by Region (2024-2034) & (US$ Million)
Table 103. APAC Virus Like Particles Sales Quantity by Region (2018-2023) & (K Dose)
Table 104. APAC Virus Like Particles Sales Quantity by Region (2024-2034) & (K Dose)
Table 105. Middle East, Africa and Latin America Virus Like Particles Sales Quantity by Company (2018-2023) & (K Dose)
Table 106. Middle East, Africa and Latin America Virus Like Particles Revenue by Company (2018-2023) & (US$ Million)
Table 107. Middle East, Africa and Latin America Virus Like Particles Sales Quantity by Type (2018-2023) & (K Dose)
Table 108. Middle East, Africa and Latin America Virus Like Particles Sales Quantity by Type (2024-2034) & (K Dose)
Table 109. Middle East, Africa and Latin America Virus Like Particles Revenue by Type (2018-2023) & (US$ Million)
Table 110. Middle East, Africa and Latin America Virus Like Particles Revenue by Type (2024-2034) & (US$ Million)
Table 111. Middle East, Africa and Latin America Virus Like Particles Sales Quantity by Application (2018-2023) & (K Dose)
Table 112. Middle East, Africa and Latin America Virus Like Particles Sales Quantity by Application (2024-2034) & (K Dose)
Table 113. Middle East, Africa and Latin America Virus Like Particles Revenue by Application (2018-2023) & (US$ Million)
Table 114. Middle East, Africa and Latin America Virus Like Particles Revenue by Application (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Virus Like Particles Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 116. Middle East, Africa and Latin America Virus Like Particles Revenue by Country (2018-2023) & (US$ Million)
Table 117. Middle East, Africa and Latin America Virus Like Particles Revenue by Country (2024-2034) & (US$ Million)
Table 118. Middle East, Africa and Latin America Virus Like Particles Sales Quantity by Country (2018-2023) & (K Dose)
Table 119. Middle East, Africa and Latin America Virus Like Particles Sales Quantity by Country (2024-2034) & (K Dose)
Table 120. GlaxoSmithKline Company Information
Table 121. GlaxoSmithKline Description and Overview
Table 122. GlaxoSmithKline Virus Like Particles Sales Quantity (K Dose), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 123. GlaxoSmithKline Virus Like Particles Product and Services
Table 124. GlaxoSmithKline Virus Like Particles SWOT Analysis
Table 125. GlaxoSmithKline Recent Developments
Table 126. Merck Company Information
Table 127. Merck Description and Overview
Table 128. Merck Virus Like Particles Sales Quantity (K Dose), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 129. Merck Virus Like Particles Product and Services
Table 130. Merck Virus Like Particles SWOT Analysis
Table 131. Merck Recent Developments
Table 132. Novavax Company Information
Table 133. Novavax Description and Overview
Table 134. Novavax Virus Like Particles Sales Quantity (K Dose), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 135. Novavax Virus Like Particles Product and Services
Table 136. Novavax Virus Like Particles SWOT Analysis
Table 137. Novavax Recent Developments
Table 138. Takeda Company Information
Table 139. Takeda Description and Overview
Table 140. Takeda Virus Like Particles Sales Quantity (K Dose), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 141. Takeda Virus Like Particles Product and Services
Table 142. Takeda Virus Like Particles SWOT Analysis
Table 143. Takeda Recent Developments
Table 144. Medicago Company Information
Table 145. Medicago Description and Overview
Table 146. Medicago Virus Like Particles Sales Quantity (K Dose), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 147. Medicago Virus Like Particles Product and Services
Table 148. Medicago Virus Like Particles SWOT Analysis
Table 149. Medicago Recent Developments
Table 150. MedImmune Company Information
Table 151. MedImmune Description and Overview
Table 152. MedImmune Virus Like Particles Sales Quantity (K Dose), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 153. MedImmune Virus Like Particles Product and Services
Table 154. MedImmune Virus Like Particles SWOT Analysis
Table 155. MedImmune Recent Developments
Table 156. TechnoVax Company Information
Table 157. TechnoVax Description and Overview
Table 158. TechnoVax Virus Like Particles Sales Quantity (K Dose), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 159. TechnoVax Virus Like Particles Product and Services
Table 160. TechnoVax Virus Like Particles SWOT Analysis
Table 161. TechnoVax Recent Developments
Table 162. Agilvax Company Information
Table 163. Agilvax Description and Overview
Table 164. Agilvax Virus Like Particles Sales Quantity (K Dose), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 165. Agilvax Virus Like Particles Product and Services
Table 166. Agilvax Virus Like Particles SWOT Analysis
Table 167. Agilvax Recent Developments
Table 168. Allergy Therapeutics Company Information
Table 169. Allergy Therapeutics Description and Overview
Table 170. Allergy Therapeutics Virus Like Particles Sales Quantity (K Dose), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 171. Allergy Therapeutics Virus Like Particles Product and Services
Table 172. Allergy Therapeutics Virus Like Particles SWOT Analysis
Table 173. Allergy Therapeutics Recent Developments
Table 174. Serum Institute of India Company Information
Table 175. Serum Institute of India Description and Overview
Table 176. Serum Institute of India Virus Like Particles Sales Quantity (K Dose), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 177. Serum Institute of India Virus Like Particles Product and Services
Table 178. Serum Institute of India Virus Like Particles SWOT Analysis
Table 179. Serum Institute of India Recent Developments
Table 180. GeoVax Labs Company Information
Table 181. GeoVax Labs Description and Overview
Table 182. GeoVax Labs Virus Like Particles Sales Quantity (K Dose), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 183. GeoVax Labs Virus Like Particles Product and Services
Table 184. GeoVax Labs Recent Developments
Table 185. Cytos Biotechnology Company Information
Table 186. Cytos Biotechnology Description and Overview
Table 187. Cytos Biotechnology Virus Like Particles Sales Quantity (K Dose), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 188. Cytos Biotechnology Virus Like Particles Product and Services
Table 189. Cytos Biotechnology Recent Developments
Table 190. ANGANY Genetics Company Information
Table 191. ANGANY Genetics Description and Overview
Table 192. ANGANY Genetics Virus Like Particles Sales Quantity (K Dose), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 193. ANGANY Genetics Virus Like Particles Product and Services
Table 194. ANGANY Genetics Recent Developments
Table 195. CPL Biologicals Company Information
Table 196. CPL Biologicals Description and Overview
Table 197. CPL Biologicals Virus Like Particles Sales Quantity (K Dose), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 198. CPL Biologicals Virus Like Particles Product and Services
Table 199. CPL Biologicals Recent Developments
Table 200. Xiamen Innovax Biotech Company Information
Table 201. Xiamen Innovax Biotech Description and Overview
Table 202. Xiamen Innovax Biotech Virus Like Particles Sales Quantity (K Dose), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 203. Xiamen Innovax Biotech Virus Like Particles Product and Services
Table 204. Xiamen Innovax Biotech Recent Developments
Table 205. Key Raw Materials Lists
Table 206. Raw Materials Key Suppliers Lists
Table 207. Virus Like Particles Distributors List
Table 208. Virus Like Particles Customers List
Table 209. Virus Like Particles Market Trends
Table 210. Virus Like Particles Market Drivers
Table 211. Virus Like Particles Market Challenges
Table 212. Virus Like Particles Market Restraints
Table 213. Research Programs/Design for This Report
Table 214. Key Data Information from Secondary Sources
Table 215. Key Data Information from Primary Sources
List of Figures
Figure 1. Virus Like Particles Product Picture
Figure 2. Global Virus Like Particles Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Virus Like Particles Market Share by Type in 2024 & 2034
Figure 4. Adeno-Associated Virus Product Picture
Figure 5. HIV Product Picture
Figure 6. Hepatitis B Virus Product Picture
Figure 7. Hepatitis C Virus Product Picture
Figure 8. Others Product Picture
Figure 9. Global Virus Like Particles Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 10. Global Virus Like Particles Market Share by Application in 2024 & 2034
Figure 11. Vaccines
Figure 12. Mycoviruses
Figure 13. Virus Research
Figure 14. Therapeutic and Imaging Agents
Figure 15. Others
Figure 16. Virus Like Particles Report Years Considered
Figure 17. Global Virus Like Particles Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 18. Global Virus Like Particles Revenue 2018-2034 (US$ Million)
Figure 19. Global Virus Like Particles Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 20. Global Virus Like Particles Sales Quantity 2018-2034 (K Dose)
Figure 21. Global Virus Like Particles Sales Quantity Market Share by Region (2018-2023)
Figure 22. Global Virus Like Particles Sales Quantity Market Share by Region (2024-2034)
Figure 23. North America Virus Like Particles Sales Quantity YoY (2018-2034) & (K Dose)
Figure 24. North America Virus Like Particles Revenue YoY (2018-2034) & (US$ Million)
Figure 25. Europe Virus Like Particles Sales Quantity YoY (2018-2034) & (K Dose)
Figure 26. Europe Virus Like Particles Revenue YoY (2018-2034) & (US$ Million)
Figure 27. China Virus Like Particles Sales Quantity YoY (2018-2034) & (K Dose)
Figure 28. China Virus Like Particles Revenue YoY (2018-2034) & (US$ Million)
Figure 29. APAC Virus Like Particles Sales Quantity YoY (2018-2034) & (K Dose)
Figure 30. APAC Virus Like Particles Revenue YoY (2018-2034) & (US$ Million)
Figure 31. Middle East, Africa and Latin America Virus Like Particles Sales Quantity YoY (2018-2034) & (K Dose)
Figure 32. Middle East, Africa and Latin America Virus Like Particles Revenue YoY (2018-2034) & (US$ Million)
Figure 33. The Top 10 and Top 5 Players Market Share by Virus Like Particles Sales Quantity in 2024
Figure 34. The Top 10 and Top 5 Players Market Share by Virus Like Particles Revenue in 2024
Figure 35. Virus Like Particles Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 36. Global Virus Like Particles Sales Quantity Market Share by Type (2018-2034)
Figure 37. Global Virus Like Particles Revenue Market Share by Type (2018-2034)
Figure 38. Global Virus Like Particles Sales Quantity Market Share by Application (2018-2034)
Figure 39. Global Virus Like Particles Revenue Market Share by Application (2018-2034)
Figure 40. North America Virus Like Particles Revenue Market Share by Company in 2024
Figure 41. North America Virus Like Particles Sales Quantity Market Share by Company in 2024
Figure 42. North America Virus Like Particles Sales Quantity Market Share by Type (2018-2034)
Figure 43. North America Virus Like Particles Revenue Market Share by Type (2018-2034)
Figure 44. North America Virus Like Particles Sales Quantity Market Share by Application (2018-2034)
Figure 45. North America Virus Like Particles Revenue Market Share by Application (2018-2034)
Figure 46. North America Virus Like Particles Revenue Share by Country (2018-2034)
Figure 47. North America Virus Like Particles Sales Quantity Share by Country (2018-2034)
Figure 48. U.S. Virus Like Particles Revenue (2018-2034) & (US$ Million)
Figure 49. Canada Virus Like Particles Revenue (2018-2034) & (US$ Million)
Figure 50. Europe Virus Like Particles Sales Quantity Market Share by Company in 2024
Figure 51. Europe Virus Like Particles Revenue Market Share by Company in 2024
Figure 52. Europe Virus Like Particles Sales Quantity Market Share by Type (2018-2034)
Figure 53. Europe Virus Like Particles Revenue Market Share by Type (2018-2034)
Figure 54. Europe Virus Like Particles Sales Quantity Market Share by Application (2018-2034)
Figure 55. Europe Virus Like Particles Revenue Market Share by Application (2018-2034)
Figure 56. Europe Virus Like Particles Revenue Share by Country (2018-2034)
Figure 57. Europe Virus Like Particles Sales Quantity Share by Country (2018-2034)
Figure 58. Germany Virus Like Particles Revenue (2018-2034) & (US$ Million)
Figure 59. France Virus Like Particles Revenue (2018-2034) & (US$ Million)
Figure 60. U.K. Virus Like Particles Revenue (2018-2034) & (US$ Million)
Figure 61. Italy Virus Like Particles Revenue (2018-2034) & (US$ Million)
Figure 62. Russia Virus Like Particles Revenue (2018-2034) & (US$ Million)
Figure 63. China Virus Like Particles Sales Quantity Market Share by Company in 2024
Figure 64. China Virus Like Particles Revenue Market Share by Company in 2024
Figure 65. China Virus Like Particles Sales Quantity Market Share by Type (2018-2034)
Figure 66. China Virus Like Particles Revenue Market Share by Type (2018-2034)
Figure 67. China Virus Like Particles Sales Quantity Market Share by Application (2018-2034)
Figure 68. China Virus Like Particles Revenue Market Share by Application (2018-2034)
Figure 69. APAC Virus Like Particles Sales Quantity Market Share by Company in 2024
Figure 70. APAC Virus Like Particles Revenue Market Share by Company in 2024
Figure 71. APAC Virus Like Particles Sales Quantity Market Share by Type (2018-2034)
Figure 72. APAC Virus Like Particles Revenue Market Share by Type (2018-2034)
Figure 73. APAC Virus Like Particles Sales Quantity Market Share by Application (2018-2034)
Figure 74. APAC Virus Like Particles Revenue Market Share by Application (2018-2034)
Figure 75. APAC Virus Like Particles Revenue Share by Region (2018-2034)
Figure 76. APAC Virus Like Particles Sales Quantity Share by Region (2018-2034)
Figure 77. Japan Virus Like Particles Revenue (2018-2034) & (US$ Million)
Figure 78. South Korea Virus Like Particles Revenue (2018-2034) & (US$ Million)
Figure 79. China Taiwan Virus Like Particles Revenue (2018-2034) & (US$ Million)
Figure 80. Southeast Asia Virus Like Particles Revenue (2018-2034) & (US$ Million)
Figure 81. India Virus Like Particles Revenue (2018-2034) & (US$ Million)
Figure 82. Middle East, Africa and Latin America Virus Like Particles Sales Quantity Market Share by Company in 2024
Figure 83. Middle East, Africa and Latin America Virus Like Particles Revenue Market Share by Company in 2024
Figure 84. Middle East, Africa and Latin America Virus Like Particles Sales Quantity Market Share by Type (2018-2034)
Figure 85. Middle East, Africa and Latin America Virus Like Particles Revenue Market Share by Type (2018-2034)
Figure 86. Middle East, Africa and Latin America Virus Like Particles Sales Quantity Market Share by Application (2018-2034)
Figure 87. Middle East, Africa and Latin America Virus Like Particles Revenue Market Share by Application (2018-2034)
Figure 88. Middle East, Africa and Latin America Virus Like Particles Sales Quantity Share by Country (2018-2034)
Figure 89. Middle East, Africa and Latin America Virus Like Particles Revenue Share by Country (2018-2034)
Figure 90. Brazil Virus Like Particles Revenue (2018-2034) & (US$ Million)
Figure 91. Mexico Virus Like Particles Revenue (2018-2034) & (US$ Million)
Figure 92. Turkey Virus Like Particles Revenue (2018-2034) & (US$ Million)
Figure 93. Israel Virus Like Particles Revenue (2018-2034) & (US$ Million)
Figure 94. GCC Countries Virus Like Particles Revenue (2018-2034) & (US$ Million)
Figure 95. Virus Like Particles Value Chain
Figure 96. Virus Like Particles Production Process
Figure 97. Channels of Distribution (Direct Vs Distribution)
Figure 98. Distributors Profiles
Figure 99. Bottom-up and Top-down Approaches for This Report
Figure 100. Data Triangulation
Figure 101. Key Executives Interviewed